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Abstract
Purpose To determine the long-term efficacy of adjuvant
immunotherapy with autologous cytokine-induced killer
(CIK) cells for locally advanced gastric cancer patients.
Experimental design One hundred and fifty-one patients
with stage III/IV gastric cancer who had undergone gas-
trectomy were enrolled, assigned to two groups (immuno-
therapy group versus no immunotherapy group/or control
group), and followed.
Results The 5-year overall survival (OS) and 5-year dis-
ease-free survival (DFS) rates for immunotherapy versus
control group were 32.4 versus 23.4 % (P = 0.071) and
28.3 versus 10.4 % (P = 0.044), respectively. For patients
with intestinal-type tumors, the 5-year OS and DFS rates
were significantly higher for immunotherapy (OS, 46.8 vs.
31.4 % and P = 0.045; DFS, 42.4 vs. 15.7 % and
P = 0.023). In the immunotherapy group, the mean CD3?
level, CD4? level, and CD4?/CD8? ratio increased from
50.8, 26.5, and 0.9 %, respectively, at baseline to 62.6,
35.0, and 1.4 %, respectively, 1 week after the first CIK-
cell treatment, returned to baseline after 2 months, and
maintained a higher level (60.7 ± 8.2 %, 34.2 ± 7.1 %,
and 1.3 ± 0.3 %, respectively) 2 months after 3 cycles of
immunotherapy.
Conclusions Adjuvant immunotherapy with CIK cells
prolongs DFS in patients with locally advanced gastric
cancer and significantly improves OS in patients with
intestinal-type tumors. Intestinal-type tumors could be
selected as an important indication for CIK-cell therapy.
This treatment may help improve T-lymphocyte subset
distribution and improve the host’s immune functions, but
multiple cycles are necessary for long-term therapeutic
efficacy.
Keywords Gastric cancer  Cytokine-induced killer cells 
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Introduction
The global age-adjusted gastric cancer incidence decreased
by 15 % since 1985[1]. Nevertheless, it remains an
important clinical issue in developed countries. In China,
gastric cancer is the leading cause of cancer-related death,
and the world-adjusted mortality rate from gastric cancer is
the highest in the world [2].
The prognosis of patients with locally advanced gastric
cancer is generally dismal; 5-year OS rates are generally
25 % or less even when multimodal treatment strategies
involving surgery, perioperative chemotherapy, and radia-
tion are used [3–7]. Most studies to date indicated that
adjuvant chemotherapy had little impact on the OS rate.
There is currently no standard regimen for postoperative
treatment [8]. However, although convincing data are
lacking, postoperative chemotherapy based on 5-fluoro-
uracil (5-FU) has been widely used in China.
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The immunosuppressed status of patients with cancer
has been reported previously [9, 10]. Immunosuppression
may be more serious after surgery for the treatment for
malignant diseases, including gastric cancer [11]. After
adjuvant chemotherapy, the host’s immune functions
would be expected to be further damaged because most
chemotherapeutic agents are immunosuppressive. There
has been a considerable interest in the hypothesis that
impaired immunity is common in cancer patients and that
tumor may recur unless therapy to reverse immunosup-
pression is administered together with anticancer treatment
[12]. Many reports indicate that adjuvant immunotherapy
with immune response cells or biological response modi-
fiers may augment the host immune system, leading to
improved survival [13–17]. Several studies published in
recent years on gastric cancer suggested a significant
improvement in patients receiving immunotherapy with
nonspecific immunopotentiators such as polysaccharide K
[18], bacille Calmette–Gue´rin [16], and OK-432 [19, 20].
Adjuvant immunotherapy is expected to be synergistic with
surgical resection in the treatment for malignancy [17].
Thus, adjuvant immunotherapy may represent an effective
modality to improve the survival rate of patients with
gastric cancer.
Treatment with cytokine-induced killer (CIK) cells is
one of the promising cellular immunotherapies. It has been
demonstrated that CIK cells proliferate abundantly in vitro
and can kill tumor cells directly [21]. Furthermore, CIK
cells can regulate and increase host cellular immune
function in vivo [22]. Therefore, it is biologically plausible
to investigate the use of CIK cells for immunotherapy
against residual tumor cells. The combination of CIK cells
and chemotherapy has been used in clinical practice and
has shown potential benefits in patients with recurrent
tumors [23].
We previously reported that immunotherapy with CIK
cells improved the response rate and increased the 2-year
survival rate of patients suffering from advanced gastric
cancer [24]. In the study reported here, we compared the
long-term effect of adjuvant immunotherapy with CIK
cells and chemotherapy only on the survival of patients
with locally advanced gastric cancer following gastrec-
tomy, and we investigated the changes in hosts’ cellular
immune functions after CIK-cell therapy.
Materials and methods
Study patients
All patients who had undergone gastrectomy and were
histologically confirmed gastric adenocarcinoma were
consecutively recruited through the Department of Tumor
Biological Treatment Clinic at The Third Affiliated
Hospital, University of Soochow between May 2002 and
June 2005, as part of a clinical trial study on gastric
adenocarcinoma. These patients were diagnosed and his-
tologically confirmed with stage IIIA, IIIB, or IV (M0)
according to the International Union Against Cancer
(UICC 2002) TNM system; had to have received 6 cycles
of adjuvant chemotherapy based on 5-FU; and had to have
had an Eastern Cooperative Oncology Group performance
status of 2 or less before adjuvant chemotherapy. The
exclusion criteria for eligibility were receipt of adjuvant
radiotherapy or other immunotherapy, concurrent active
malignancy, and recurrence identified within 6 months
after operation. All patients underwent R0 curative gas-
trectomy with D2 lymph node, that is, N1 and N2, dis-
section. Indications for total stomach resection were
diffuse or mixed-type cancer according to Lauren’s clas-
sification and intestinal-type tumor of the middle and
upper stomach with a proximal margin of no less than
5 cm. This study was conducted according to the princi-
ples of the Declaration of Helsinki and was approved by
the Ethics Committee of The Third Affiliated Hospital of
Soochow University. All the patients provided informed
consent prior to enrollment.
Of the 158 enrolled patients, 151 patients were eligible
for the study. If patients who received immmunotherapy
with CIK cells were treated as an ‘immunotherapy group’
or ‘treatment group’, the rest without immunotherapy were
treated as a ‘no immunotherapy group’ or ‘control group’.
Induction of CIK cells and determination of their
cytotoxic activity
The peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll-Conray density gradient centrifugation,
as described previously [25], and were collected using
blood cell separators (Baxter, Deerfield, IL, USA). The
number of seeded PBMCs is about 1 9 107. After the
viability of the PBMCs was assessed by trypan blue
exclusion, the PBMCs (2.0 9 106/ml) were plated onto
6-well dishes (Nunc, Roskilde, Denmark) and cultured with
Medium I containing RPMI 1640 in the presence of human
interferon-gamma (1.0 9 106 U/L, Shanghai Fosun
Pharma Co., Shanghai, China); recombinant human inter-
leukin 2 (5.0 9 105 U/L, Shandong Quanguang Pharma-
ceutical Co., Quanguang, China); 10 % inactivated human
serum; 25 mM HEPES; and 2 mM L-glutamine. The cells
were incubated in a humidified atmosphere with 5 % CO2
at 37 C. After 24 h, monoclonal antibody against CD3
(100 lg/L, Antibody Diagnostic Inc., New York, NY,
USA) and interleukin-1 alpha (1.0 9 105 U/L, Promega
Biological Products, Ltd., Shanghai, China) were added.
After another 48 h, the supernatant was removed by
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aspiration and the cells were cultured in Medium II
(Medium I without interferon-gamma). The medium was
replaced every 3 days. On days 1, 7, 14, 21, and 28, the
cells were identified and sorted by flow cytometry (Beck-
man-Coulter, Fullerton, CA, USA). Before infusion, the
viability of CIK was tested by the dye-exclusion with no
less than 95 % viable cells. The cytotoxic activity of the
CIK cells was determined by co-incubation with the natural
killer cell-sensitive K562 cell line (American Type Culture
Collection, Manassas, VA, USA) as described previously
[24].
Treatments
Before enrollment in this study, all patients received 6
cycles of multidrug adjuvant chemotherapy based on 5-FU.
The patients in the immunotherapy group received at least
3 cycles of CIK-cell therapy after adjuvant chemotherapy
unless recurrence was ascertained. The patients in the
control group did not receive immunotherapy. The first
cycle was started 6 weeks after the end of adjuvant che-
motherapy, and the subsequent cycles were started at the
intervals of 8–12 weeks. More than 1 9 109 CIK cells
were transfused into patients within 1 h every second day
via superficial vein. Five transfusions were defined as 1
cycle. When the patients in either the immunotherapy
group or the control group were diagnosed with recurrence,
second-line chemotherapy or palliative surgery was
performed.
Follow-up
The postoperative baseline and follow-up investigations
were documented. The baseline assessments included a
complete medical history, physical examination, and
diagnostic imaging, including abdominal ultrasonography
or computed tomography and chest radiography.
Follow-up was the same for the immunotherapy and
control groups, and performed every 3 months for the
first 2 years after CIK-cell therapy, every 6 months for
the next 3 years, and yearly thereafter. Follow-up con-
sisted of physical examination, blood counting, liver
function, CEA level, abdominal ultrasonography or
computed tomography, and chest radiography. Gastros-
copy was also performed for patients in whom regional
recurrence was suspected. In patients with recurrence
and patients who died, the site and date of the first
recurrence and the date of death were recorded. Disease
recurrence was diagnosed by physical and radiological
examinations, and routine histological examinations
were carried our as needed. Patients were followed up
until they were lost to follow-up or died or until October
25, 2010.
In the immunotherapy group, lymphocyte subsets were
detected by flow cytometry in peripheral blood 2 weeks
after the completion of adjuvant chemotherapy (baseline)
and 1 and 8 weeks after the start of every cycle of CIK-cell
therapy. In the control group, lymphocyte subsets were
detected by flow cytometry 6 months after the completion
of adjuvant chemotherapy.
Statistical analysis
Differences in distribution of selected demographic and
clinical characteristics between the immunotherapy and
control groups were evaluated using the Student’s t test and
v2 test. Lymphocyte subsets before and after CIK therapy
were compared by the paired-sample t test, and continuous
data at multiple time points in the same individual were
analyzed by repeated-measures analysis of variance. The
main end point was overall survival (OS). Secondary end
points were disease-free survival (DFS) and cellular
immune response. OS and DFS were defined as the time
from the date of operation to the date of death from any
cause or the first occurrence of a neoplastic event (relapse
or second malignancy) or the date of the last follow-up.
Participants who were alive or recurrence free at the end of
the study period or lost to follow-up were censored. OS and
DFS curves were estimated using the Kaplan–Meier
method, and the Cox’s model for hazard ratio (HR) and
95 % confidence interval (CI) was performed for compar-
ison of the immunotherapy with control groups. Multivar-
iable model was adjusted with possible underlying
variables that were statistically significant in the univariate
analysis. P \ 0.05 was considered statistically significant.
Data were analyzed using SPSS software (version 13.0,
SPSS Inc., Chicago, IL, USA.).
Results
Patient characteristics
A total of 158 patients were recruited for the study at The
Third Affiliated Hospital of Soochow University from
April 2002 to June 2005. Seven patients were excluded as 4
patients in immunotherapy group were refused further
CIK-cell therapy after the first cycle; the other 3 were in
the control group and received other immunotherapies after
enrollment. Therefore, the final analyses included 151 eli-
gible patients, 77 in the control group, and 74 in the
immunotherapy group. There were no significant differ-
ences in demographic and clinical characteristics between
the 2 groups except that the proportion of female patients
was higher in the immunotherapy group (P = 0.037)
(Table 1).
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Induction of CIK cells
The proliferation and phenotypes of the PBMCs after CIK
induction varied between individuals. The cell number
increased more than 100-fold on average after 14-day incu-
bation. The number of CIK (CD3?CD56?) cells increased
greatly, from 400-fold to more than 1,400-fold depending on
the individual, with an average of 700-fold. The number of
CIK cells peaked at day 14 and then slightly decreased by day
28. All CIK cells administered met the following criteria: The
percentages of CD3? and CD8? cells exceeded 70 and 40 %,
respectively, and CD3?CD56? cells were no less than 30 %.
The cytotoxic activity of the CIK cells was highest at day 14
(70.5 ± 5.2 %). These results are similar to those in our
previously published articles [24, 26]. The final cell products
were assessed for viability by the dye-exclusion test and
checked twice for possible contamination by bacteria, fungi,
and endotoxins. At least 1 9 109 CIK cells were harvested
and transfused into patients within 1 h every second day since
day 14 to day 22 for 5 times.
OS and DFS
Three patients (1 in the immunotherapy group and 2 in the
control group) were not followed up, and they were cen-
sored at the time of their last visit. Four patients in the
immunotherapy group received only 2 cycles of CIK-cell
therapy because the recurrence was diagnosed within
6 months after adjuvant chemotherapy. These patients
were not excluded from the study in order to keep balance
between the 2 groups.
The median follow-up period was 50.5 months (range,
18–82 months). By the end of follow-up, 137 patients
(90.7 %) had died, and 143 patients (94.7 %) had been
diagnosed with recurrence. The causes of death and sites of
recurrence are shown in Table 2. Of the patients with
recurrence, 54.5 % had a hematogenous recurrence which
was most frequent, 27.3 % had a peritoneal recurrence,
19.6 % had a lymphatic recurrence, 18.2 % had a locore-
gional recurrence, and 19.6 % had multiple forms of
recurrence. The hematogenous recurrence rate of the
Table 1 Demographic and
clinical characteristics of
patients





Characteristic Total (n = 151) Chemotherapy only




Sex, male/female 101/50 58/19 43/31 0.037
Age (year), median ± SE 57.0 ± 1.2 56 ± 1.5 58 ± 2.1 0.692
ECOG performance status
0/1 136 69 67 0.915
2 15 8 7
Surgical procedure
Partial gastrectomy 82 39 40 0.745
Total gastrectomy 69 38 34
Location of tumor
Upper 39 18 21 0.772
Middle 41 22 19
Lower 71 37 34
Pathological type of tumor
Intestinal type 98 51 47 0.598
Diffuse 42 22 20
Mixed type 11 4 7
Histologic differentiation
Well differentiated 41 23 18 0.644
Poorly differentiated 78 37 41
Signet-ring cell 32 17 15
UICC stage
IIIA 46 24 22 0.837
IIIB 72 35 37
VI 33 18 15
Chemotherapy regimen
Cisplatin 28 18 10 0.101
Oxaliplatin 79 34 45
Docetaxel 44 25 19
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immunotherapy group was 50.0 %, which was moderately
lower than that of the control group (58.7 %); however, the
difference between the groups was not significant. Tumor-
related deaths accounted for 78.5 % of the deaths in the
immunotherapy group and 88.9 % of the deaths in the control
group. Univariate analysis showed that the following factors
were associated with improved OS: lower grade (P = 0.000),
smaller tumor size (P = 0.007), younger age (P = 0.000),
lower tumor location (P = 0.007), earlier tumor UICC stage
(P = 0.000), and partial gastrectomy (P = 0.001). In con-
trast, sex, chemotherapy regimen, and performance status did
not significantly influence OS.
OS and DFS curves between the immunotherapy and
control groups are presented in Figs. 1 and 2, respectively.
The patients in immunotherapy group had a borderline sig-
nificantly and significantly better OS and DFS than the
patients in control group (log-rank, P = 0.071 for OS and
P = 0.044 for DFS), respectively. The 3- and 5-year OS rates
were 54.5 and 23.4 % in the control group versus 67.6 and
32.4 % in the immunotherapy group. The median OS dura-
tions were 42.1 months in the control group and 48.1 months
in the immunotherapy group. In contrast, the 3- and 5-year
DFS rates were 36.4 and 10.4 % in the control group versus
47.3 and 28.3 % in the immunotherapy group. The median
DFS durations were 34.1 months in the control group and
40.4 months in the immunotherapy group. Furthermore,
compared with the patients in the control group, the patients in
immunotherapy group had borderline and significantly
reduced risk of overall death and recurrence (HR, 0.78; 95 %
CI, 0.53–1.04 for overall death and HR, 0.72; 95 % CI,
0.52–0.99 for recurrence), respectively.
A retrospective subgroup analysis of patients by Lau-
ren’s histological type showed that patients with diffuse or
mixed-type tumors seemed not to benefit from adjuvant
immunotherapy. The OS and DFS were not significantly
different between the 2 groups (log-rank, P = 0.970 for OS
and P = 0.962 for DFS, Fig. 3). Within this subgroup, the
3- and 5-year OS rates were 38.5 and 7.7 % in the control
group versus 40.7 and 7.4 % in the immunotherapy group.
The 3- and 5-year DFS rates were 11.5 and 0.0 % in the
control group and 14.8 and 3.7 % in the immunotherapy
group. In addition, there was no significant difference in
risk of overall death and recurrence between the control
group and the immunotherapy group (HR, 1.01; 95 % CI,
0.57–1.74 for overall death and HR, 0.98; 95 % CI, 0.57–1.69
for recurrence). However, for the patients with intestinal-type
Table 2 Death (with causes)
and recurrence (with sites) of
patients
a Multiple recurrences are
included
Characteristic Total (n = 151) Chemotherapy only
(control) (n = 77)
Immunotherapy
(n = 74)
Death 137 (90.7) 72 (93.5) 65 (87.8)
Tumor related 115 (83.9) 64 (88.9) 51 (78.5)
Intercurrent disease 8 (5.8) 3 (4.2) 5 (7.7)
Second malignancy 5 (3.6) 2 (2.8) 3 (4.6)
Unknown cause 9 (6.6) 3 (4.2) 6 (9.2)
Site of recurrencea
Hematogenous 78 (54.5) 44 (58.7) 34 (50.0)
Peritoneal 39 (27.3) 19 (25.3) 20 (29.4)
Lymphatic 28 (19.6) 14 (18.7) 14 (20.6)
Locoregional 26 (18.2) 12 (16.0) 13 (19.1)
Fig. 1 Kaplan–Meier estimates for overall survival (OS) for patients.
Continuous line immunotherapy group; dotted line chemotherapy-
only group (control). Log-rank: P = 0 0.071
Fig. 2 Kaplan–Meier estimates for disease-free survival (DFS) for
patients. Continuous line immunotherapy group; dotted line chemo-
therapy-only group (control). Log-rank: P = 0.044
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tumors, not only OS but also DFS was significantly better in
the immunotherapy group than in the control group (log-rank,
P = 0.045 for OS and P = 0.023 for DFS, respectively,
Fig. 4). The 3- and 5-year OS rates were 62.7 and 31.4 % in
the control group versus 87.2 and 46.8 % in the immuno-
therapy group. The 3- and 5-year DFS rates were 49.0 and
15.7 % in the control group versus 66.0 and 42.4 % in the
immunotherapy group. The patients in immunotherapy group
had significantly reduced risk in overall death and recurrence
compared with the patients in the control group (HR, 0.65;
95 % CI, 0.43–1.00 for overall death and HR, 0.62; 95 % CI,
0.41–0.95 for recurrence).
Cellular immune response after CIK-cell therapy
We evaluated the cellular immune response in the immu-
notherapy group by analyzing changes in lymphocyte
subsets between baseline (2 weeks after adjuvant chemo-
therapy) and various points during immunotherapy shown
in Table 3. At baseline, the percentages of CD3?, CD4?
Fig. 3 Kaplan–Meier estimates for OS (a) and DFS (b) for patients
with diffuse or mixed-type tumors. Continuous line immunotherapy
group; dotted line chemotherapy-only group (control). Log-rank:
P = 0.970 for OS and P = 0.962 for DFS
Fig. 4 Kaplan–Meier estimates for OS (a) and DFS (b) for patients
with intestinal-type tumors. Continuous line immunotherapy group;
dotted line chemotherapy-only group (control). Log-rank: P = 0.045
for OS and P = 0.023 for DFS















CD3? 50.8 ± 8.5 62.6 ± 11.3* 51.8 ± 9.2 60.7 ± 8.2*
CD4? 26.5 ± 6.1 36.0 ± 6.6 28.0 ± 7.6 34.2 ± 7.1
CD4?/CD8? 0.9 ± 0.4 1.4 ± 0.3* 1.0 ± 0.2 1.3 ± 0.3*
CIK cytokine-induced killer
*P \ 0.05 compared to before CIK therapy
a CCT Cycle of CIK therapy
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cells, and the CD4?/CD8? ratio were 50.8 ± 8.5 %,
26.5 ± 6.1 %, and 0.9 ± 0.4, respectively. One week after
the end of the first CIK-cell treatment cycle, the percent-
ages of CD3?, CD4? cells, and the CD4?/CD8? ratio were
significantly higher (62.6 ± 11.3 %, 36.0 ± 6.6 %, and
1.4 ± 0.3, respectively). By 2 months after the end of the
first treatment cycle, the values declined to near baseline
values (51.8 ± 9.2 %, 28.0 ± 7.6 %, and 1.0 ± 0.2 %,
respectively). Two months after the end of the third cycle
of CIK-cell treatment, values increased to 60.7 ± 8.2 %,
34.2 ± 7.1 %, and 1.3 ± 0.3, respectively, which was
significant higher than the baseline. Additionally, the
changes of immunologic data in the different subgroups
were compared according to Lauren’s histological type.
Compared to the patients with intestinal-type cancer, sim-
ilar cellular immune responses were observed in the
patients with diffuse-type and mixed-type cancer.
Side effects of CIK-cell transfusion
A total of 351 cycles of CIK-cell therapy were performed.
Two patients received 2 cycles, 18 patients received 3
cycles, 32 patients received 4–5 cycles, 22 patients
received more than 6 cycles, and the rest of 77 patients
were in the control group. During and after each of the 351
cycles of CIK-cell therapy that were administered, side
effects, including fever, chills, headache, rash, nausea and
vomiting, diarrhea, shock, abnormalities of routine blood
test, hepatic dysfunction, and renal dysfunction, were
recorded. The most common side effects were fever
(20.8 %), chills (15 %), headache (10 %), rash (5 %), and
nausea and vomiting (5 %). There were no instances of
diarrhea, shock, abnormalities of routine blood test, hepatic
dysfunction, or renal dysfunction (Table 4). All of the side
effects were resolved without intervention within 24 h or
were treated successfully by simple allopathy, such as anti-
inflammatory treatment, anti-allergy treatment, and antie-
metic treatment.
Discussion
In this study, we assessed the efficacy of adoptive immu-
notherapy with CIK cells in patients with locally advanced
gastric cancer after gastrectomy. To our knowledge, no
studies of adjuvant adoptive immunotherapy with immune
response cells for gastric cancer have previously been
reported. Studies have shown that immune response cells
such as lymphokine-activated killer cells [27], tumor-
infiltrating lymphocytes [28], anti-CD3 monoclonal anti-
body-induced killer cells [29], and CIK cells may kill
tumor cells directly with high proliferative activity [30].
These cells are non-major histocompatibility complex-
restricted in target cell recognition and killing [31]. Inter-
estingly, CIK cells have also been shown to be effective
against multidrug-resistant and FasL-positive malignant
cells [22, 32]. Moreover, CIK cells can regulate and
increase host cellular immune function in vivo by secretion
of cytokines, such as interferon-gamma, and a number of
chemokines, including RANTES, MIP-1a, and MIP-1b
[22, 33]. Because of their inherently high antitumor
activity, CIK cells represent one of the promising cellular
immunotherapies. Studies have shown that CIK cells from
tumor patients (autologous CIK cells) have a high prolif-
eration rate and cytotoxic activity in vitro and have shown
the efficacy and safety of transfusing such cells to patients
with advanced cancer [24, 26, 34, 35].
In a previous study [24], we have reported the number of
CIK-cell therapy to cancer-related death in gastric cancer,
showing significant differences in the survival for 156
gastric cancer patients. In the current study, we evaluated
the effect of adjuvant immunotherapy with CIK cells after
chemotherapy on survival of patients with locally advanced
gastric cancer. In order to better balance between the two
groups, we set the baseline at the end of six cycles of
adjuvant chemotherapy. Therefore, both the patients with
early stage (stage I/II) and those without completion of six
cycles of adjuvant chemotherapy or recurrence within
6 months after surgery were excluded. We found an
improvement of 9 % in 5-year OS rate (P = 0.071) and an
improvement of 17.9 % in 5-year DFS rate (P = 0.044) in
the patients receiving adjuvant immunotherapy. Moreover,
the stratified analysis by Lauren’s histological type
revealed that patients with intestinal-type tumors, but not
those with diffuse or mixed-type tumors, responded to
immunotherapy. For the patients with intestinal-type
tumors, not only OS but also DFS was significantly longer
in the immunotherapy group than in the control group. The
Table 4 Side effects of CIK-cell therapy (351 cycles)
Side effects Fever Chills Headache Rash Nausea and vomiting Shock
Yes 73 (20.8) 52 (14.8) 35 (10.0) 18 (5.10) 18 (5.10) 0 (0.00)
No 278 (79.2) 299 (85.2) 316 (90.0) 333 (94.9) 333 (94.9) 100 (100)
CIK cytokine-induced killer
Values in table are numbers and percentages of cycles in which side effects were observed
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interpretation of these findings should be treated with
caution as it is an exploratory analysis within a subgroup.
Interestingly, response of patients with intestinal-type
tumors to immunotherapy was observed in another study
[16]. In that study, a nonspecific immunopotentiator,
bacille Calmette–Gue´rin (BCG), was added to chemo-
therapy. Treatment with BCG was started within 2 weeks
after the beginning of chemotherapy and continued for
2 years or until death. The study indicated that adjuvant
immunotherapy (BCG ? FAM) might prolong the survival
of gastric cancer patients after gastrectomy, in particular, in
patients with pT2/T3 tumors and intestinal-type primary
tumors [16]. In agreement with what has been suggested by
previous data [36, 37], our study indicated that Lauren’s
histological type is an important prognostic factor, while
diffuse and mixed-type tumors are associated with an
invasive growth pattern and short survival time [38]. It is
well known that neither nonspecific immunopotentiators
nor immune response cells can improve the host’s immune
system function immediately after a short treatment pro-
cedure. This may be an important reason why patients with
diffuse and mixed-type tumors do not benefit from
immunotherapy—disease advances rapidly or patients die
before immunotherapy can have an important effect.
In patients with advanced stages of cancer, the normal
immune response is frequently observed to be altered or
impaired [39]. Typically, immune function is evaluated by
using parameters reflecting either functional or numerical
changes of T lymphocytes. The measurement of T-lym-
phocyte subsets has been reported to be a useful clinical
indicator of immunosuppression in a number of disease
states [40]. In this study, we found that the percentage of
CD3? cells and the ratio of CD4? to CD8? cells were
lower than the normal reference values. Similar results
have been reported previously by others [11]. We also
found that the percentages of CD3?, CD4? cells, and the
ratio of CD4?/CD8? were significantly higher 1 week after
the first cycle of CIK-cell therapy but had declined mark-
edly at 2 months. However, 2 months after 3 cycles of
immunotherapy, these values maintained a higher level
than the baselines. These results indicate that CIK-cell
therapy is helpful to improve the T-lymphocyte subset
distribution, but the improvement resulting from a single
cycle of therapy is short-lived. Therefore, to gain long-term
therapeutic efficacy, multiple cycles of therapy should be
administered.
At present, convincing data from large-scale clinical
studies of adjuvant chemotherapy for gastric cancer are
lacking. There is no standard regimen for adjuvant che-
motherapy, although chemotherapy has been found to be
active in the treatment for unresectable or metastatic gas-
tric cancer in China. As the main purpose of this study was
to evaluate the efficacy of sustained CIK-cell therapy after
adjuvant chemotherapy, we set up a baseline at the end of 6
cycles of adjuvant chemotherapy. This could be a limita-
tion of this study without a standard regimen of adjuvant
chemotherapy. In addition, a selection bias was another
limitation of this study because this was a hospital-based
study, and a limited number of patients in each group may
not represent the patient population from which the patients
arose. Therefore, larger and well-designed studies are
needed to confirm our findings. As described previously by
others [24, 26, 36], we also observed that CIK-cell therapy
was well tolerated. CIK-cell transfusion was associated
with no severe side effects, and the slight side effects that
were noted, such as chills, fever, headache, and nausea and
vomiting, were all eliminated by moderate treatment.
In conclusion, these results indicate that CIK-cell ther-
apy is helpful to improve the host’s immune function after
chemotherapy, but multiple cycles are necessary for long-
term therapeutic efficacy. Adjuvant immunotherapy with
CIK cells can prolong DFS in patients with locally
advanced gastric cancer who have undergone gastrectomy
and may have a noticeable impact on OS in patients with
intestinal-type tumors in particular.
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